Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

PURPOSE: This phase II study investigated daily or weekly sapanisertib (a selective dual inhibitor of mTOR complexes 1 and 2) in combination with fulvestrant. PATIENTS AND METHODS: Postmenopausal women with estrogen receptor–positive (ER(+))/HER2-negative (HER2(−)) advanced or metastatic breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Sáenz, José Á., Martínez-Jáñez, Noelia, Cubedo, Ricardo, Jerez, Yolanda, Lahuerta, Ainhara, González-Santiago, Santiago, Ferrer, Nieves, Ramos, Manuel, Alonso-Romero, Jose L., Antón, Antonio, Carrasco, Eva, Chen, Jingjing, Neuwirth, Rachel, Galinsky, Kevin, Vincent, Sylvie, Leonard, E. Jane, Slamon, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365359/
https://www.ncbi.nlm.nih.gov/pubmed/34980598
http://dx.doi.org/10.1158/1078-0432.CCR-21-2652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365359/
https://www.ncbi.nlm.nih.gov/pubmed/34980598
http://dx.doi.org/10.1158/1078-0432.CCR-21-2652

Ejemplares similares